David Martin PhD
Stock Analyst at Bloom Burton
(4.74)
# 673
Out of 4,649 analysts
232
Total ratings
53.1%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12.00 | $3.90 | +207.69% | 51 | Aug 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Maintained: Buy | $40.00 | $34.15 | +17.13% | 3 | Aug 13, 2026 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $6.00 → $6.50 | $5.34 | +21.72% | 14 | Aug 12, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 | $15.47 | -3.04% | 34 | Aug 10, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $12.00 | $9.32 | +28.76% | 29 | Aug 7, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $5.00 → $7.08 | $2.14 | +230.74% | 4 | Aug 5, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $19.53 | $9.31 | +109.82% | 6 | Aug 3, 2026 | |
| TSX: CRRX CareRx Corporation | Maintained: Buy | $5.00 | $3.25 | +53.85% | 12 | Jul 31, 2026 | |
| HELP Cybin | Maintained: Buy | $47 | $11.99 | +291.99% | 8 | Jul 21, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $35 → $36 | $25.12 | +43.31% | 13 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16.50 → $18.00 | $15.20 | +18.42% | 14 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $0.50 → $0.40 | $0.30 | +33.33% | 13 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $74 | $62.35 | +18.68% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.37 → $4.00 | $0.46 | +769.57% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $11.38 | -20.91% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $22.08 | -36.05% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.20 → $19.00 | $18.25 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.21 | n/a | 2 | Jul 6, 2025 |
HLS Therapeutics Inc.
Aug 13, 2026
Maintained: Buy
Price Target: $12.00
Current: $3.90
Upside: +207.69%
Apotex Health Corp.
Aug 13, 2026
Maintained: Buy
Price Target: $40.00
Current: $34.15
Upside: +17.13%
Medexus Pharmaceuticals Inc.
Aug 12, 2026
Maintained: Buy
Price Target: $6.00 → $6.50
Current: $5.34
Upside: +21.72%
Aurinia Pharmaceuticals
Aug 10, 2026
Maintained: Hold
Price Target: $15
Current: $15.47
Upside: -3.04%
Knight Therapeutics Inc.
Aug 7, 2026
Maintained: Buy
Price Target: $12.00
Current: $9.32
Upside: +28.76%
PYC Therapeutics Limited
Aug 5, 2026
Maintained: Buy
Price Target: $5.00 → $7.08
Current: $2.14
Upside: +230.74%
Eupraxia Pharmaceuticals Inc.
Aug 3, 2026
Maintained: Buy
Price Target: $19.53
Current: $9.31
Upside: +109.82%
CareRx Corporation
Jul 31, 2026
Maintained: Buy
Price Target: $5.00
Current: $3.25
Upside: +53.85%
Cybin
Jul 21, 2026
Maintained: Buy
Price Target: $47
Current: $11.99
Upside: +291.99%
Zymeworks
Jun 29, 2026
Maintained: Buy
Price Target: $35 → $36
Current: $25.12
Upside: +43.31%
Jun 4, 2026
Maintained: Buy
Price Target: $16.50 → $18.00
Current: $15.20
Upside: +18.42%
May 15, 2026
Maintained: Buy
Price Target: $0.50 → $0.40
Current: $0.30
Upside: +33.33%
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $62.35
Upside: +18.68%
Dec 11, 2025
Maintained: Buy
Price Target: $8.37 → $4.00
Current: $0.46
Upside: +769.57%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $11.38
Upside: -20.91%
Oct 21, 2025
Maintained: Buy
Price Target: $14
Current: $22.08
Upside: -36.05%
Jul 18, 2025
Maintained: Buy
Price Target: $20.20 → $19.00
Current: $18.25
Upside: n/a
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.21
Upside: n/a